The Federal Commission for the Protection against Sanitary Risks (Cofepris) authorized a clinical trial for a drug that would serve as a kind of vaccine against HIV, as well as a new drug for the treatment of leukemia.
In the first case, the trial seeks to evaluate the efficacy and safety of the drug lenacapavir, which must be administered subcutaneously twice a year, for pre-exposure prophylaxis to HIV in people aged 16 years and older who are in risk of infection by this virus.
According to a biweekly report on therapeutic expansion, Cofepris also endorsed another five clinical trials and 24 new drugs, including a new one for the treatment of chronic myeloid leukemia and a biotechnological one against anemia.
Read also: Mexico authorizes a new drug for the treatment of HIV
In addition, the agency authorized 121 medical devices, of which 32 are dedicated to medical care; Notable on the list are thrombectomy and coronary angioplasty catheters, as well as surface-mounted bone vibration digital hearing aids.
Among the supplies endorsed by Cofepris are 59 new devices to diagnose toxoplasmosis, carbapenemase and to measure the sensitivity of slow-growing non-tuberculous mycobacteria, as well as 30 new medical equipment, such as intravascular ultrasound and spectroscopy, and a Loop mobile imaging robot -X.
We recommend: The sixth successful case of HIV remission after a bone marrow transplant is confirmed
Do you already have us on Facebook? Give us like and receive the best information
2023-08-22 20:54:00
#Cofepris #authorizes #trial #vaccine #HIV #treatment #leukemia
